Thor Medical ASA

As of June 30, 2022, Thor Medical ASA carries a market capitalization of 292.52M, placing it among publicly traded companies globally. Its enterprise value stands at 5.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Thor Medical ASA's next confirmed earnings release is scheduled for March 3, 2027.

As of June 30, 2022, Thor Medical ASA has 119.10M shares outstanding.

These figures are as of June 30, 2022.

As of June 30, 2022, Thor Medical ASA maintains a current ratio of 2.50, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is - -, indicating a certain level of leverage, while an interest coverage ratio of -1,369.64 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2022, Thor Medical ASA posted a negative return on equity (ROE) of -155.90, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -107.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 39.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2022, Thor Medical ASA recorded 1.16M in income tax expense. The company reported a pretax loss of -432.98M and -434.14M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Thor Medical ASA's stock has gained approximately 23.76% over the past 52 weeks. The 50-day moving average sits at 5.07, while the 200-day moving average is 4.75.

Over the twelve months ended June 30, 2022, Thor Medical ASA generated - - in revenue and converted that into -434.14M in net income, yielding earnings per share of -4.01. EBITDA reached -430.07M, while operating income came in at -440.49M.

As of June 30, 2022, Thor Medical ASA holds 287.44M in cash and equivalents against - - in total debt, resulting in a net debt position of -287.44M. Total book value stands at 182.55M, with working capital of 185.85M providing operational flexibility.

Thor Medical ASA produced -393.65M in operating cash flow over the twelve months ended June 30, 2022. After subtracting -150,000.00 in capital expenditures, free cash flow totaled -393.80M - equivalent to -3.63 per share.

These figures cover the twelve months ended June 30, 2022. Free cash flow yield is negative at -147.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -76.39, meaning Thor Medical ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Thor Medical ASA's most recent stock split took place on June 19, 2025.

As of June 30, 2022, Thor Medical ASA has an Altman Z-Score of -2.84, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.